The COVID-19 Shock: Reshaping Diabetes Care Through Telemedicine

When the COVID-19 pandemic swept across the globe in early 2020, healthcare systems were forced to pivot almost overnight. For the estimated 537 million adults living with diabetes worldwide, the disruption was particularly acute. The disease itself increases the risk of severe COVID-19 outcomes, yet routine care—blood glucose monitoring, medication adjustments, foot checks, and lab work—could not simply pause. Telemedicine, a term that once implied niche convenience, became the primary channel for delivering diabetes care during lockdowns and social distancing mandates. This article examines how telemedicine enabled continuity of care for diabetes patients during the pandemic, the benefits and persistent challenges, and the long-term implications for chronic disease management.

The rapid adoption of remote care technologies was fueled by necessity. A study from the Journal of Diabetes Science and Technology reported that telehealth visits for diabetes increased by over 3,000% in the early months of the pandemic compared to the previous year. This shift was not merely about replacing in-person appointments; it fundamentally changed how patients and providers interacted, leveraging video consultations, continuous glucose monitors (CGMs), smart insulin pens, and cloud-based data sharing to maintain glycemic control from a distance.

While the pandemic served as a catalyst, the lessons learned are now shaping the future of diabetes management. Understanding what worked, what fell short, and what needs improvement is essential for building resilient care models that can serve patients beyond public health emergencies.

The Unique Vulnerability of People With Diabetes During COVID-19

The intersection of diabetes and COVID-19 created a perfect storm. According to the Centers for Disease Control and Prevention, adults with diabetes are at higher risk for severe illness from the virus, including hospitalization, ICU admission, and death. This reality made avoiding in-person healthcare settings a priority. Yet diabetes requires consistent medical oversight: insulin dose adjustments based on dynamic glucose trends, periodic A1c checks, and management of comorbidities like hypertension and kidney disease.

During the initial wave, many endocrinology clinics and primary care offices suspended non-urgent appointments. Patients reported delays in prescription renewals, missed routine screenings, and reduced access to diabetes education. A survey by the American Diabetes Association found that nearly half of respondents experienced disruptions in care during the first six months of the pandemic, with those from lower-income households and minority groups disproportionately affected. Telemedicine emerged as the bridge, but its effectiveness depended heavily on infrastructure, patient readiness, and policy flexibility.

Evidence quickly accumulated that telemedicine could achieve comparable outcomes. A meta-analysis published in Diabetes Care in 2021 examined 12 randomized controlled trials and found that patients using telehealth for diabetes management had similar or improved glycemic control compared to usual care, particularly when interventions included remote monitoring and feedback. The key was that telemedicine had to be more than a video call—it required integration with data from devices and timely clinician response.

Core Telemedicine Modalities Deployed During the Pandemic

Video Consultations for Clinical Decision-Making

Live video visits became the backbone of telemedicine during COVID-19. Platforms like Zoom for Healthcare, Doxy.me, and integrated EHR solutions allowed endocrinologists to conduct history-taking, review glucose logs, adjust medications, and address patient concerns in real time. Many providers found that video consultations were surprisingly effective for routine follow-ups, as they could see patients’ homes, medication organization, and even insulin injection techniques. However, the inability to perform physical exams—especially foot and eye evaluations—remained a limitation, often requiring deferred in-person visits once safe.

Remote Patient Monitoring With Connected Devices

Perhaps the most transformative element was the widespread use of continuous glucose monitors (CGMs) such as Dexcom, Abbott’s Freestyle Libre, and Medtronic Guardian. These devices transmit glucose data to smartphones and cloud-based platforms, allowing clinicians to review trends remotely. Many clinics set up dashboards that alerted them to patients with concerning patterns—recurrent hypoglycemia, prolonged hyperglycemia, or missed sensor readings—enabling proactive outreach. A study from the Mayo Clinic found that CGM data sharing reduced average A1c by 0.6% over three months during telehealth-initiated interventions.

Beyond CGMs, smart insulin pens (like InPen) recorded dosing timestamps and amounts, helping providers identify patterns like missed doses or correction stacking. Bluetooth-enabled blood pressure cuffs and scales allowed for basic cardiovascular monitoring, while some patients used smartphone-connected urine ketone test strips for sick-day management.

Mobile Health Applications and Digital Coaching

Apps such as mySugr, Glucose Buddy, and One Drop became integrated into care plans. Patients could log meals, activity, medication, and glucose readings, with the ability to share reports directly with their care team. Several programs incorporated artificial intelligence to provide real-time recommendations, such as insulin bolus calculators or carbohydrate counting assistance. Digital coaching platforms, like Virta Health and Livongo, paired patients with certified diabetes educators and health coaches via messaging and video sessions, often leading to sustained improvements in weight and glycemic control.

Advantages That Go Beyond Crisis Management

Uninterrupted Access to Specialist Care

For patients in rural or underserved regions, telemedicine dismantled geographic barriers. Endocrinologists, who are in short supply nationwide, could see patients from hundreds of miles away without requiring hours of travel. This was especially valuable during the pandemic when many specialists were redeployed to COVID-19 units or had reduced clinic hours. Telemedicine also enabled multidisciplinary care—patients could see their endocrinologist, dietitian, and mental health provider in a single virtual visit, improving care coordination.

Data-Driven Personalization

The shift to telemedicine incentivized patients to adopt digital tools that generated rich datasets. Rather than relying on a snapshot of glucose values from a fingerstick logbook, clinicians could view 24-hour CGM curves showing postprandial spikes, fasting trends, and overnight patterns. This granularity allowed for precise insulin titration and lifestyle recommendations. Some platforms used machine learning to predict hypoglycemic events based on historical data and real-time inputs, enabling preemptive adjustments.

Empowerment Through Education and Self-Management

Many healthcare organizations moved their Diabetes Self-Management Education and Support (DSMES) programs online. Virtual group classes covered topics like insulin injection technique, carbohydrate counting, exercise planning, and sick-day management. Patients could join from home, often with family members who also benefited from the information. Recorded sessions allowed for review, and online portals hosted quizzes and tracking tools. Research indicates that virtual DSMES is as effective as in-person education in improving A1c and self-care behaviors, provided participants have adequate digital access.

Reduced Infection Risk and Convenience

Beyond COVID-19, telemedicine protects immunocompromised patients from seasonal influenza, respiratory syncytial virus, and other contagious illnesses. The convenience of not having to take time off work, arrange transportation, or navigate busy waiting rooms reduced the burden of care and likely improved appointment adherence. A survey by the Journal of Medical Internet Research found that 82% of diabetes patients who used telemedicine during the pandemic reported high satisfaction, with convenience cited as the top reason.

Persistent Hurdles That Must Be Addressed

The Digital Divide in Access and Affordability

Telemedicine’s success depends on reliable internet, a compatible device, and often a subscription to a data plan. According to the Federal Communications Commission, approximately 14 million Americans lack broadband access, and many more cannot afford data plans. Older adults with diabetes—who represent a significant proportion of the patient population—are less likely to own smartphones or be comfortable with video calls. The American Diabetes Association’s survey highlighted that patients over 65 and those with lower incomes were far less likely to participate in video visits, relying instead on telephone calls that lacked the visual component essential for effective care.

Efforts to bridge this gap include device loaner programs, partnerships with libraries to offer Wi-Fi hotspots, and the development of low-bandwidth platforms that work on basic mobile phones. Some health systems also utilized community health workers to help patients set up and navigate telemedicine tools.

Digital Literacy and Training Gaps

Even with access, many patients struggle with the technical aspects: creating accounts, troubleshooting camera issues, uploading meter data, or reading CGM reports. Clinicians also reported burnout from having to provide technical support during visits, reducing time for medical care. Structured onboarding—including one-on-one training sessions, simplified user guides with screenshots, and family member involvement—can reduce these frictions. Some clinics integrated telemedicine orientation into the first visit, walking patients through the process step-by-step.

Privacy, Security, and Regulatory Compliance

Despite HIPAA enforcement flexibilities during the public health emergency, concerns about data breaches and unauthorized access remained. Patients hesitated to share sensitive health data over unsecured networks, while providers worried about liability. As telemedicine normalizes, healthcare organizations must implement end-to-end encryption, multi-factor authentication, and clear data-sharing policies. Patient education on privacy protections can also build trust.

What Telemedicine Cannot Replace

Some components of diabetes care demand in-person encounters: comprehensive foot exams to detect neuropathy, ulcerations, or Charcot changes; dilated eye exams for retinopathy screening; and calibrated blood pressure measurements. A1c testing requires a blood draw, though home collection kits have emerged. Hybrid care models have therefore gained traction: routine visits happen virtually every 3–6 months, while annual in-person exams are scheduled for eyes, feet, and labs. Risk-stratified approaches ensure that patients with poor control or complications receive more frequent in-person attention.

Insurance and Reimbursement Uncertainty

During the pandemic, Medicare, Medicaid, and many private insurers temporarily waived restrictions on telemedicine, covering video visits at the same rate as in-office care. However, these waivers were time-limited in many jurisdictions. Some insurers reverted to lower reimbursement for virtual consultations or imposed stricter requirements (e.g., audio-only not covered, need for prior authorization). The inconsistency created administrative burdens for providers and discouraged long-term investment in telemedicine infrastructure. Advocacy for permanent parity in reimbursement, as supported by the Endocrine Society, is crucial to sustaining remote care.

Building a Better System: Implementation Strategies That Work

Drawing from pandemic-era experiences, healthcare organizations can adopt several evidence-based strategies to optimize telemedicine for diabetes management:

  • Invest in equity from the start: Offer free or low-cost devices and data plans to low-income patients. Use mobile-first platforms that work on smartphones with older operating systems. Provide technical support in multiple languages, including Spanish and Mandarin.
  • Create standardized onboarding workflows: Develop quick-start guides, video tutorials, and appointment-based training sessions. Assign a care coordinator to assist patients who need extra help. Integrate device pairing and data-sharing setup into the first telemedicine visit.
  • Use data dashboards for population management: Implement platforms that aggregate CGM, blood pressure, and medication data across the patient panel. Set automatic alerts for critical values, missed check-ins, or poor glucose control. Enable proactive outreach rather than reactive visits.
  • Adopt hybrid care pathways: Define clear protocols for when virtual care is appropriate and when in-person visits are mandatory. For example, patients with stable A1c and no complications can have two virtual visits per year plus one in-person comprehensive exam; those with uncontrolled diabetes or recent hypoglycemia events require more frequent in-person assessment.
  • Integrate behavioral health and peer support: Embed screening for diabetes distress and depression into virtual visits. Offer online group sessions led by certified diabetes educators and mental health professionals. Facilitate virtual peer support groups where patients share coping strategies.

The Horizon: What Comes Next for Telemedicine in Diabetes Care

Artificial Intelligence and Predictive Analytics

Artificial intelligence is poised to transform telemedicine from reactive to predictive. Algorithms can analyze CGM data to forecast hypoglycemic events 30–60 minutes in advance, issuing alerts to patients and caregivers. Machine learning models are being developed to automatically adjust insulin pump basal rates based on activity, meal timing, and stress levels detected by wearables. Companies like Dexcom and Tandem Diabetes Care already integrate AI-driven insights into their platforms, and future iterations may enable fully closed-loop systems (artificial pancreas) that communicate remotely with clinicians.

Expanded Use of Wearables and Sensors

Beyond CGMs, new sensors are entering the market: implantable glucose sensors that last up to 90 days, sweat-based monitors for ketones, and smart insulin patches that deliver doses based on real-time readings. Smartwatch algorithms measure heart rate variability, sleep quality, and physical activity, all of which affect glucose regulation. Combining these data streams into a unified dashboard accessible during telemedicine visits will allow clinicians to make more holistic recommendations.

Integrated Virtual Care Platforms

Healthcare systems are moving toward platforms that unify video visits, remote monitoring data, EHR integration, patient education, and billing under one interface. These systems reduce the need for clinicians to toggle between multiple applications and streamline patient experience. Some platforms, such as Glooko and Diasend, already aggregate data from over 200 diabetes devices and present it in standardized reports that can be reviewed during a telemedicine encounter.

Policy and Payment Reform

The long-term viability of telemedicine for diabetes management hinges on policy decisions. The Centers for Medicare & Medicaid Services have permanently expanded coverage for certain telehealth services, but restrictions remain on audio-only consultations and geographic originating site requirements. State laws also vary widely. Continued advocacy from organizations like the American Diabetes Association and JDRF is needed to ensure that telemedicine remains accessible, equitable, and adequately reimbursed.

Behavioral Health Integration as Standard of Care

Diabetes distress, depression, and anxiety are common, yet often underdiagnosed. Telemedicine platforms are beginning to incorporate validated screening tools (e.g., PHQ-9, diabetes distress scale) that patients can complete before a virtual visit. Results are automatically scored and flagged for clinician review. Virtual consultations with behavioral health specialists integrated into diabetes care teams have shown to improve medication adherence, glycemic control, and quality of life.

Key Takeaways for Clinicians and Patients

  • Telemedicine is an effective tool for diabetes management that was rapidly adopted during the COVID-19 pandemic. It can maintain or improve glycemic control when paired with remote monitoring and timely clinician feedback.
  • Equitable access remains the greatest challenge; targeted efforts to provide devices, internet, and digital literacy training are necessary to prevent widening health disparities.
  • Hybrid care models that combine virtual visits with periodic in-person exams for foot, eye, and lab assessments offer a sustainable structure for comprehensive diabetes care.
  • Emerging technologies—AI, wearables, smart insulin pens, and integrated platforms—will further enhance the capacity of telemedicine to deliver personalized, proactive care.
  • Permanent policy changes on reimbursement, data security, and regulatory flexibility are essential to lock in the gains made during the pandemic and ensure telemedicine remains a core component of diabetes management.

The COVID-19 pandemic acted as an unprecedented accelerator for telemedicine in diabetes care. What began as a crisis response has revealed a path toward more accessible, data-driven, and patient-centered management. While barriers persist—especially around digital equity and reimbursement—the collective experience of clinicians, researchers, and patients has proven that remote care can be both safe and effective. By continuing to innovate and address structural challenges, the healthcare system can ensure that telemedicine remains a durable asset in the fight against diabetes, long after the pandemic recedes.